STX-6398 / Soley Therapeutics - LARVOL DELTA

CKAP2 modulation with a novel small molecule results in excellent in-vitro and in-vivo anti tumor activity (AACR 2026) - "In conclusion, we have discovered a first-in-class, oral small molecule which modulates CKAP2 and its downstream pathways indicating very good anti-tumor activity both in-vitro and in-vivo. This novel therapy is being considered as a promising therapeutic candidate for the treatment of CKAP2 expressing cancers."

Preclinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026 (Businesswire) - "Preclinical studies of STX-6398 demonstrate selective anti-tumor activity. In a 300-tumor cell line panel, sensitivity to STX-6398 correlated with CKAP2 protein abundance across cancer types, supporting a biomarker-linked therapeutic approach in both hematologic and solid tumors....In vivo, oral administration of STX-6398 demonstrated significant anti-tumor activity across multiple xenograft models, including lung and colon cancer, with dose-dependent tumor growth inhibition and regression."

Preclinical • Colon Cancer • Hematological Malignancies • Non Small Cell Lung Cancer

Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at AACR 2026 (Businesswire) - "The AACR presentation will describe the discovery and preclinical characterization of STX-6398, an oral small molecule that modulates CKAP2 and its downstream signaling pathways. Studies demonstrate selective anti-tumor activity in vitro and in vivo, with efficacy observed across preclinical models following oral administration."

Preclinical • Oncology